Download Free Sample
Table of Contents
Liver cancer diagnostics involves tests and procedures used to diagnose liver cancer such as blood tests, imaging tests and tissue biopsies. Liver cancer is the sixth most common diagnosed cancer and the second leading cause of death from cancer around the world. It is more common in men than women with its highest incidence in the age group of 45 to 60 years. Increasing prevalence of liver cancer, adoption of new techniques for diagnosis, increasing research & development in liver cancer diagnosis are some major factors driving the growth of liver cancer diagnostics market. The positive growth rate of the market is induced by the discovery and development of new imaging tests, biomarkers that might help in detecting small tumors.
Researchers are using peptides that attach to cancer cells in liver. These peptides are linked to dyes that can be seen with a CT scan or MRI to find specific facts about the size, shape and location of tumors. Liver cancer diagnostics market is expected to witness promising growth in the forecast period due to rising awareness, encouraging government initiatives for effective prevention and control of disease and rising frequency of liver cancer screening among high risk populations.
Screening type segment is divided into imaging, lab tests, endoscopy, biopsy and others. Lab tests are primary method of liver cancer diagnosis and accounts around 30% market share of screening type segment in 2024. Lab tests include range of blood and urine tests. Blood test helps in determining whether the liver is functioning properly or not. Most commonly performed blood tests for liver cancer detection include alpha-fetoprotein test, serum alkaline phosphatase test etc. Imaging segment was the fastest growing segment with highest CAGR. The growth was attributed to the increased demand for non-invasive imaging tests such as CT scan, Ultrasonography and MRI which are widely used to diagnose liver cancer and opt suitable treatment.
Competitive analysis included in research study helps users to understand key players market positioning and marketing strategies. Global liver cancer diagnostics market is witnessing growth due to continuous research and development in the area of genomics and proteomics which is expected to yield new, more sophisticated and specialized diagnostic tests. The market is witnessing increased competition from international players and private hospital chains which are investing in their own diagnostic capabilities. Small players do not have the deep pockets to invest in research and development like larger companies which makes them potential acquisition targets and drives industry consolidation.
Consolidating imaging and laboratories into a one-stop service companies are offering cost effective services. Some are trying to boost R&D efforts by forming joint ventures, acquisitions, partnerships with smaller, innovative players to advance product offerings. For instance in July 2019 Exact Sciences, known for their Cologuard colorectal cancer screening test has agreed to purchase Genomic Health in a $2.8 billion deal. Several players are receiving capital investments to improve the portfolio in the area of genomics and proteomics which is expected to yield new, more sophisticated and specialized diagnostic tests and deliver liver cancer diagnostic services at affordable cost.
Applications segment is divided into Hospitals, Physical Examination Centers and Cancer Research Institutes. The hospitals account for the major chunk of the application segment it is expected to grow at highest CAGR through 2025-2031. The growth in hospital segment was attributed to the rising demand for diagnostic testing, growing number of hospitals with imaging modalities and screening facilities. Physical Examination Centers was the fastest growing segment in 2024 with highest CAGR. With rising check-ups for cancers screening the physical examination centers have observed relative increase in demand to meet the industry requirements.
Regional outlook of research study is based on analysis of Market in North America, Europe, Asia Pacific, Middle East, South America, and Africa & Rest of the World. North America dominates the global liver cancer diagnostics market. The growth in the region is primarily due to presence of advanced healthcare infrastructure, sophisticated medical facilities, key players and growing prevalence of liver cancer. According to Centers for Disease Control and Prevention each year about 24,000 men and 10,000 women get liver cancer in United States and about 18,000 men and 9,000 women die from the disease. Europe was second largest region in terms of revenue generation in 2023 and is expected to grow at significant pace due to presence of world-class cancer research institutions, medical centres and hospitals along with rising incidence of liver cancer in the region.
Asia Pacific was fastest growing market with rising incidences of liver cancer in countries like China, India and Japan. The burden of disease is snowballing in China. In 2024, around a quarter of Liver Cancer incident cases and deaths occurred in Asia, with China alone accounting for around half of the global burden. Proactive measures of government to raise awareness regarding infectious diseases, investments on development of healthcare infrastructure, lowering cancer diagnostics costs, developing biopharmaceutical sector has brought significant growth opportunities in the region.
Global Liver Cancer Diagnostics Market : Screening Type
Global Liver Cancer Diagnostics Market : Application
Global Liver Cancer Diagnostics Market : Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study consists of following key players in Global Liver Cancer Diagnostics Market :
Geographical analysis of Global Liver Cancer Diagnostics Market :
Global Liver Cancer Diagnostics Market Report delivers a comprehensive analysis of the following parameters:
Parameters | Details |
---|---|
Base Year |
2024 |
Historical Data |
2018-2023 |
Forecast Data |
2024-2030 |
Base Year Value (2024) |
USD 9932.77 million |
Forecast Value (2031) |
USD 15194.78 million |
CAGR (2025-2030) |
6.7 % |
Regional Scope |
North America, Europe, Asian Pacific, Latin America, Middle East and Africa, and ROW |
Liver Cancer Diagnostics Market was valued at around USD 9932.77 million in 2023 & estimated to reach USD 15194.78 million by 2030.
Liver Cancer Diagnostics Market is likely to grow at Compound Annual Growth Rate (CAGR) of 6.7% between 2024 to 2030.
Lab tests are the primary method of liver cancer diagnosis and account for around 30% market share of the screening type segment in 2023. Asia Pacific region is likely to show the highest growth rate between 2024 to 2030.
Some of the top companies included in the research report are Abcodia, Abbott Diagnostics, AXO Science SAS, BioMark Technologies, Bioprognos SL, Sky One Medica, Glycotest, Digna Biotech SL.
Primary driving factors for the growth of the Liver Cancer Diagnostics Market include Increasing prevalence of liver cancer, adoption of new techniques for diagnosis, increasing research & development in liver cancer diagnosis.
Yes, the report includes COVID 19 impact on the market.
Inquire Before Buying
We are committed to offering 100 % free customization while purchasing.
Receive a detailed insight into the Liver Cancer Diagnostics Market research study with our FREE sample report delivered straight to your email. The report covers major market factors such as Revenue, Forecast, Top companies insight, Regional analysis, Market trends & more.
Download Free Sample